Subscribe

ASCO 2014 - Colorectal and Head & Neck Cancer

Lapatinib is a tyrosine kinase inhibitor of both EGFT and ErbB2, both of which are overexpressed in up to 90% and 40% of patients with SCCHN.
In many cancers, KRAS mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents.
In the E2399 trial, HPV+ patients with oropharyngeal squamous cell carcinoma (OPSCC) attained 2-year overall survival (OS) of 95% and progression-free survival (PFS) of 86% when treated with induction chemotherapy (IC) and 70 Gy chemoradiation.
Platinum-based chemoradiation therapy (CRT) is the current standard treatment for locally advanced SCCHN, and induction docetaxel/cisplatin/5-fluorouracil (TPF) is superior to cisplatin/5-fluorouracil alone, but it has not been tested when added to concomitant therapy.
This was a retrospective analysis of the phase 3 IMCL-9815 trial assessing the role of HPV-p16 status in patients with locally advanced SCCHN receiving radiation therapy (RT) plus cetuximab (cetux) or RT alone (Rosenthal DI, et al. ASCO 2014. Abstract 6001).
The optimal maintenance therapy following combination chemotherapy plus bevacizumab (Bev) is still open to controversy.
The phase 3 CAIRO3 study investigated the efficacy of maintenance treatment with capecitabine plus bevacizumab (C + B) versus observation alone in patients with mCRC who were not progressing following induction with chemotherapy plus bevacizumab (CAPOX-B) (Koopman M, et al. ASCO 2014. Abstract 3504).
Mismatch repair (MMR) status is an important prognostic factor in patients with colorectal cancer.
A previous clinical study established preoperative chemoradiotherapy, total mesorectal excision (TME) surgery, and adjuvant chemotherapy with 5-fluorouracil (5-FU) as the standard treatment for locally advanced rectal cancer (LA-RC).
The addition of cetuximab to FOLFOX4 significantly improves progression-free survival and overall response rate (ORR) when used as first-line therapy in patients with mCRC with KRAS exon 2 wild-type (WT), whereas patients with KRAS exon 2 mutation (mut) show no benefit from the addition of cetuximab.
Page 1 of 3
Results 1 - 10 of 21
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology